Our Mission

The case for evidence-based
peptide access

The Peptide Access Alliance exists because the gap between what the science shows and what patients can legally access has grown unacceptable. We are here to close it — through advocacy, education, and accountability.

Mission Statement
“The Peptide Access Alliance advances safe, evidence-based, and equitable access to peptide therapeutics — translating science into policy, building trust in the supply chain, and empowering practitioners, researchers, and patients to make informed decisions.”
Why We Exist

A system built for barriers, not access

Peptide therapeutics occupy a peculiar regulatory no-man’s-land. Many have decades of peer-reviewed research behind them. Some are naturally occurring compounds the human body produces. Yet the regulatory infrastructure around them — FDA bulk substance nominations, 503A/503B compounding restrictions, scheduling considerations — has not kept pace with the science.

The result is a bifurcated market: practitioners and patients who can navigate the system get access; those who cannot are left to a gray market with no quality assurance and no accountability. Neither outcome is acceptable.

PAA was founded to change that. Not by circumventing the regulatory system, but by engaging it — holding it accountable to evidence, building the trust infrastructure the market lacks, and making the science legible to the people who need it most.

503A/B
Compounding frameworks that restrict access to dozens of peptides with established safety profiles
FDA regulatory pathway
~40+
Therapeutic peptides studied in human trials, many unavailable through legal channels in the US
Research-to-access gap
$0
Dedicated advocacy infrastructure for peptide access prior to PAA’s formation
The gap we’re filling
How We Operate

Three pillars, one mission

Each pillar reinforces the others. Policy work requires credible research. Research requires trusted suppliers. Trusted suppliers drive better policy outcomes.

01
Policy & Advocacy
We engage regulators, legislators, and public health stakeholders directly. We submit formal comment letters, build coalitions, and translate complex regulatory questions into plain-language public communication. Our goal is a policy environment where access reflects evidence — not commercial pressure or bureaucratic inertia.
Federal & State Engagement
02
Research & Education
We translate peer-reviewed peptide science into plain-language summaries that are honest about what the evidence shows — and equally honest about where it doesn’t reach. We build a research library that practitioners, policymakers, and curious patients can actually use.
Evidence Translation
03
Vendor Certification
We certify peptide suppliers against a rigorous framework covering purity, manufacturing, labeling, and transparency — giving consumers a trusted signal and giving compliant vendors a meaningful competitive differentiator. Certified vendors are listed in the PAA public registry.
Quality Assurance
What We Stand For

Our values

Evidence before advocacy
We do not advocate for access to compounds we cannot defend with evidence. Every position we take is grounded in peer-reviewed research, and we are transparent about the strength of that evidence — including its limitations.
Access as a health equity issue
A regulatory system that only works for people with resources is not a fair system. We fight for frameworks where access is determined by evidence and safety, not by income, geography, or the ability to navigate opaque bureaucratic channels.
Accountability in the supply chain
The gray market thrives in the absence of accountability infrastructure. We build that infrastructure — not to restrict access, but to make the existing market safer for everyone in it.
Intellectual honesty
We distinguish between animal studies and human trials. We note funding sources. We flag conflicts of interest. When the evidence is weak, we say so. The credibility of our advocacy depends on the integrity of our research communication.
Looking Forward

Our vision

“A future where every person — regardless of income, geography, or regulatory complexity — can access evidence-backed peptide therapeutics from suppliers they can trust, guided by research they can understand.”

Our Policy Positions Join the Alliance →